These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 22434539

  • 1. FMS Kinase Inhibitors: Current Status and Future Prospects.
    El-Gamal MI, Anbar HS, Yoo KH, Oh CH.
    Med Res Rev; 2013 May; 33(3):599-636. PubMed ID: 22434539
    [Abstract] [Full Text] [Related]

  • 2. Autocrine inhibition of the c-fms proto-oncogene reduces breast cancer bone metastasis assessed with in vivo dual-modality imaging.
    Jeffery JJ, Lux K, Vogel JS, Herrera WD, Greco S, Woo HH, AbuShahin N, Pagel MD, Chambers SK.
    Exp Biol Med (Maywood); 2014 Apr; 239(4):404-13. PubMed ID: 24599884
    [Abstract] [Full Text] [Related]

  • 3. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
    Ohno H, Kubo K, Murooka H, Kobayashi Y, Nishitoba T, Shibuya M, Yoneda T, Isoe T.
    Mol Cancer Ther; 2006 Nov; 5(11):2634-43. PubMed ID: 17121910
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. c-FMS inhibitors: a patent review.
    Burns CJ, Wilks AF.
    Expert Opin Ther Pat; 2011 Feb; 21(2):147-65. PubMed ID: 21204725
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Transforming mechanism of the feline sarcoma virus encoded v-fms oncogene product.
    Tamura T, Hadwiger-Fangmeier A, Simon E, Smola U, Geschwill H, Schütz B, Trouliaris S, Boscheck B, Niemann H, Bauer H.
    Behring Inst Mitt; 1991 Jul; (89):93-9. PubMed ID: 1834054
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The colony-stimulating factor 1 (CSF-1) receptor (c-fms proto-oncogene product) and its ligand.
    Rettenmier CW, Roussel MF, Sherr CJ.
    J Cell Sci Suppl; 1988 Jul; 9():27-44. PubMed ID: 2978516
    [Abstract] [Full Text] [Related]

  • 19. Macrophage accumulation at a site of renal inflammation is dependent on the M-CSF/c-fms pathway.
    Le Meur Y, Tesch GH, Hill PA, Mu W, Foti R, Nikolic-Paterson DJ, Atkins RC.
    J Leukoc Biol; 2002 Sep; 72(3):530-7. PubMed ID: 12223521
    [Abstract] [Full Text] [Related]

  • 20. c-Cbl associates directly with the C-terminal tail of the receptor for the macrophage colony-stimulating factor, c-Fms, and down-modulates this receptor but not the viral oncogene v-Fms.
    Mancini A, Koch A, Wilms R, Tamura T.
    J Biol Chem; 2002 Apr 26; 277(17):14635-40. PubMed ID: 11847211
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.